Harvard Bioscience Inc (HBIO) stock
HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/3017% above fair value
$9.00−0.08 (-0.88%)
Close on Nov 18, 2026Market cap $40.97MP/E –Yield –
Harvard Bioscience revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Harvard Bioscience's revenue for the twelve months ending Jun 30, 2026 was $87.81M, down 1.1% year over year. For fiscal 2025 it was $86.55M, down 8.1% from the year before. Over ten years it grew -2.2% a year on average. The highest annual figure on record is $120.77M in fiscal 2018.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.55M | -8.1% |
| FY2024 | Dec 31, 2024 | $94.14M | -16.1% |
| FY2023 | Dec 31, 2023 | $112.25M | -1.0% |
| FY2022 | Dec 31, 2022 | $113.34M | -4.7% |
| FY2021 | Dec 31, 2021 | $118.90M | +16.5% |
| FY2020 | Dec 31, 2020 | $102.10M | -12.1% |
| FY2019 | Dec 31, 2019 | $116.18M | -3.8% |
| FY2018 | Dec 31, 2018 | $120.77M | +56.0% |
| FY2017 | Dec 31, 2017 | $77.41M | -25.9% |
| FY2016 | Dec 31, 2016 | $104.52M | -3.8% |
| FY2015 | Dec 31, 2015 | $108.66M | +0.0% |
| FY2014 | Dec 31, 2014 | $108.66M | +3.3% |
| FY2013 | Dec 31, 2013 | $105.17M | -5.4% |
| FY2012 | Dec 31, 2012 | $111.17M | +2.1% |
| FY2011 | Dec 31, 2011 | $108.86M | +0.6% |
| FY2010 | Dec 31, 2010 | $108.18M | +26.1% |
| FY2009 | Dec 31, 2009 | $85.77M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.73M | +11.1% |
| Q1 FY2026 | Mar 31, 2026 | $20.76M | -4.7% |
| Q4 FY2025 | Dec 31, 2025 | $23.74M | -3.3% |
| Q3 FY2025 | Sep 30, 2025 | $20.59M | -6.3% |
| Q2 FY2025 | Jun 30, 2025 | $20.45M | -11.5% |
| Q1 FY2025 | Mar 31, 2025 | $21.77M | -11.2% |
| Q4 FY2024 | Dec 31, 2024 | $24.56M | -12.8% |
| Q3 FY2024 | Sep 30, 2024 | $21.97M | -13.4% |
| Q2 FY2024 | Jun 30, 2024 | $23.10M | -19.7% |
| Q1 FY2024 | Mar 31, 2024 | $24.51M | -18.2% |
| Q4 FY2023 | Dec 31, 2023 | $28.15M | -1.0% |
| Q3 FY2023 | Sep 30, 2023 | $25.36M | -5.8% |
| Q2 FY2023 | Jun 30, 2023 | $28.76M | -1.5% |
| Q1 FY2023 | Mar 31, 2023 | $29.98M | +4.2% |
| Q4 FY2022 | Dec 31, 2022 | $28.43M | -14.0% |
| Q3 FY2022 | Sep 30, 2022 | $26.92M | -9.2% |
| Q2 FY2022 | Jun 30, 2022 | $29.21M | +0.0% |
| Q1 FY2022 | Mar 31, 2022 | $28.78M | +6.6% |
| Q4 FY2021 | Dec 31, 2021 | $33.06M | +6.7% |
| Q3 FY2021 | Sep 30, 2021 | $29.66M | +23.4% |
| Q2 FY2021 | Jun 30, 2021 | $29.20M | +25.3% |
| Q1 FY2021 | Mar 31, 2021 | $26.99M | +13.5% |
| Q4 FY2020 | Dec 31, 2020 | $30.98M | +0.0% |
| Q3 FY2020 | Sep 30, 2020 | $24.04M | -12.3% |
| Q2 FY2020 | Jun 30, 2020 | $23.31M | -21.2% |
| Q1 FY2020 | Mar 31, 2020 | $23.77M | -15.7% |
| Q4 FY2019 | Dec 31, 2019 | $30.97M | -8.5% |
| Q3 FY2019 | Sep 30, 2019 | $27.42M | -4.3% |
| Q2 FY2019 | Jun 30, 2019 | $29.58M | -6.1% |
| Q1 FY2019 | Mar 31, 2019 | $28.20M | +5.4% |
| Q4 FY2018 | Dec 31, 2018 | $33.86M | +56.4% |
| Q3 FY2018 | Sep 30, 2018 | $28.64M | +53.0% |
| Q2 FY2018 | Jun 30, 2018 | $31.52M | +66.3% |
| Q1 FY2018 | Mar 31, 2018 | $26.76M | +48.0% |
| Q4 FY2017 | Dec 31, 2017 | $21.65M | -18.1% |
| Q3 FY2017 | Sep 30, 2017 | $18.72M | -25.2% |
| Q2 FY2017 | Jun 30, 2017 | $18.96M | – |
| Q1 FY2017 | Mar 31, 2017 | $18.09M | – |
| Q4 FY2016 | Dec 31, 2016 | $26.42M | – |
| Q3 FY2016 | Sep 30, 2016 | $25.01M | – |
See a number that looks wrong?